SCHEMBL6408354

SCHEMBL6408354

Fc1ccc(-c2ccnc(-c3cc(-c4ccc(F)cc4)ccn3)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.55
MAPKAPK2 P49137 2/20 0.47
TGFBR1 P36897 1/20 0.45
RAB9A P51151 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
MAP4K4 O95819 2/20 0.42
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
GFER P55789 1/20 0.41
PHF8 Q9UPP1 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX5 P09917 1/20 0.39
MAPK14 Q16539 1/20 0.39
CCR1 P32246 1/20 0.39
CCR5 P51681 1/20 0.39
CCR8 P51685 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28802099 0.88 KDM4E (0.50) MAPK10MAPKAPK2TGFBR1MAP4K4CYP3A4
SCHEMBL14184255 0.87 MAPK10 (0.45) MAPK10MAPKAPK2TGFBR1RAB9AMEN1
SCHEMBL27562868 0.86 TGFBR1 (0.54) MAPK10MAPKAPK2TGFBR1MAP4K4MAPT
SCHEMBL13045222 0.86 MAPK10 (0.44) MAPK10MAPKAPK2TGFBR1RAB9AMEN1
SCHEMBL23278789 0.85 TGFBR1 (0.52) MAPK10MAPKAPK2TGFBR1MAPTTOP1
Propane SCHEMBL4417404 0.85 MAPKAPK2 (0.50) MAPK10MAPKAPK2TGFBR1RAB9AMEN1
SCHEMBL28605297 0.82 MEN1 (0.47) MAPK10MAPKAPK2TGFBR1RAB9AMEN1
SCHEMBL19238779 0.81 MAPT (0.55) MAP4K4MAPTCCR1CCR5CCR8
SCHEMBL16526776 0.79 CYP1A2 (0.51) MAPK10TGFBR1RAB9AMEN1NPC1
SCHEMBL21001790 0.78 DYRK1A (0.59) MAPK10RAB9AMEN1KMT2AMAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP claimed
US-20050233233-A1 Luminescent lanthanide complexes with imine ligands and devices made with such complexes RADU NORA S 2005-10-20 US claimed
EP-1406909-A1 LUMINESCENT LANTHANIDE COMPLEXES WITH IMINE LIGANDS AND DEVICES MADE WITH SUCH COMPLEXES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2004-04-14 EP claimed
US-20030129450-A1 Luminescent lanthanide complexes with imine ligands and devices made with such complexes LG CHEM, LTD. (KR) 2003-07-10 US claimed
WO-2003008424-A1 LUMINESCENT LANTHANIDE COMPLEXES WITH IMINE LIGANDS AND DEVICES MADE WITH SUCH COMPLEXES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-01-30 WO claimed
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233233-A1 Luminescent lanthanide complexes with imine ligands and devices made with such complexes SSB, LARP7, LIG3 MAPK10 3812/4885MAPKAPK2 4459/4885TGFBR1 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.